Roche Clinical Trials
Roche ensured HUF 4,411 million in savings for the pharmaceutical budget in 2019 through clinical trials. Clinical trials have now become an indispensable part of patient care in Hungary. With their help, otherwise extremely costly therapies are becoming available to patients free of charge under highly controlled conditions, closely monitoring the efficacy and safety of investigational medicinal products. In 2019, Roche conducted 64 clinical trials in 6 therapeutic areas in Hungary.
Consequently, Hungarian physicians are becoming part of the innovation in their specialist fields and gain firsthand experience with the most advanced products and methodological innovations. Overall, the professional and scientific skills and international recognition of Hungarian medical science is growing. The clinical trials conducted in Hungary are also extremely advantageous for public finances: as capital investments, they improve operating conditions, equipment and quality of service within the health sector. In addition, as the trials create jobs, it is also helping to keep Hungarian physicians in the country. The involvement of Hungarian supplier partners also benefits the national economy. In our clinical trials, the medicinal products are provided by our company, thus the burden of the financer is reduced and their resources can be optimised. With its clinical trials, Roche has helped to save HUF 4,4 bn (CHF 15,1 mio) for the Hungarian drug budget.
Clinical trials have now become an indispensable part of patient care in Hungary. With their help, otherwise extremely costly therapies are becoming available to patients free of charge under highly controlled conditions, closely monitoring the efficacy and safety of investigational medicinal products.
Often, illnesses can be treated in this way for which there is no publicly funded therapy, or officially authorized therapies are not yet available. In such cases, social responsibility is indispensable; our objective is to make sure that patients can have access to the treatment they need at the right time. This also requires continuous information and patient education, to which Roche pays outstanding attention.
In 2019 Roche involved 720 Hungarian patients in clinical trials across 117 sites. In total, we conducted 64 research studies across six therapeutic areas such as oncology, immunology/inflammatory disease, neurology/psychiatry, pulmonology, hematology/nephrology, and ophthalmology. The majority of our trials are still related to oncology, but we are launching more and more in neurology and ophthalmology as well.
In the 21st century, the boundaries between genetic research, drug and IT innovation are fading; in the new scientific discipline, which is just developing, Roche plays a leading role. Creating and routinely applying a genetic profile in diagnostics, personalised therapies assigned to the profile, and the integration of health data as ‘Big Data’ and their analysis are only a few examples of the innovations examples of the innovations that are solutions of the present and no longer the future, solutions that are also available in Hungary.
Data published here are for informative purposes only, they don’t substitute medical check-ups. If you need further information, please turn to your treating physician.